Chemomab Therapeutics News - CMMB

Company Name	Stock Ticker Symbol	Market	Type
Chemomab Therapeutics Ltd	CMMB	NASDAQ	Depository Receipt

	Price Change	Change Percent	Stock Price	Last Traded
	-0.0191	-2.90%	0.6399	17:56:01

Open Price	Low Price	High Price	Close Price	Prev Close
0.6394	0.62	0.6464	0.6399	0.659

more quote information »

Recent News

Date	Time	Source	Heading
4/24/2024	07:00	GLOBE	Chemomab Therapeutics to Report First Quarter 2024 Financial..
4/18/2024	07:00	GLOBE	Chemomab Reports New Peer-Reviewed Publication Reinforcing..
4/02/2024	07:00	GLOBE	Chemomab to Host Virtual Key Opinion Leader Webinar on..
3/25/2024	07:06	GLOBE	Chemomab Awarded New European Patent for CM-101, Its..
3/07/2024	07:00	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
3/07/2024	07:00	PRNUS	Chemomab Therapeutics Announces Year End and Fourth Quarter..
3/05/2024	07:00	PRNUS	Chemomab Therapeutics to Participate in Leerink Global..
2/20/2024	09:20	APS	Biotech Shares Massively Bid Up Before Opening Bell
2/20/2024	07:00	PRNUS	Chemomab Awarded New Patents for CM-101, Its First-in Class..
2/14/2024	07:00	PRNUS	Chemomab Therapeutics to Report Fourth Quarter and Full Year..
2/05/2024	07:00	PRNUS	Chemomab Therapeutics to Participate in Upcoming Investor..
1/30/2024	07:00	PRNUS	Chemomab Therapeutics Announces New Publication Reinforcing..
1/03/2024	07:00	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/03/2024	07:00	PRNUS	Chemomab Announces Completion of Patient Enrollment in..
11/16/2023	07:00	PRNUS	Chemomab Presentation at ACR Convergence 2023 Provides..
11/15/2023	16:35	EDGAR2	Form SC 13D/A - General statement of acquisition of..
11/15/2023	07:00	PRNUS	Chemomab Therapeutics Receives FDA Fast Track Designation..
11/13/2023	08:00	PRNUS	Chemomab Presents New Clinical Data Supporting CM-101's..
11/09/2023	08:00	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/09/2023	08:00	PRNUS	Chemomab Therapeutics Announces Third Quarter 2023 Financial..
11/06/2023	16:15	PRNUS	Chemomab Therapeutics Discloses Receipt of Nasdaq Notice..
11/06/2023	00:15	EDGAR2	Form EFFECT - Notice of Effectiveness
10/30/2023	08:33	EDGAR2	Form F-3/A - Registration statement by foreign private..
10/30/2023	07:00	PRNUS	Chemomab Therapeutics to Report Third Quarter 2023 Financial..
10/26/2023	07:00	PRNUS	Chemomab Therapeutics to Present at Upcoming Scientific..
10/16/2023	16:25	EDGAR2	Form F-3 - Registration statement by foreign private issuers
9/28/2023	07:00	PRNUS	Chemomab Therapeutics to Present Its CM-101 Clinical Program..
8/29/2023	07:00	PRNUS	Chemomab Therapeutics to Present at the H.C. Wainwright 25th..
8/14/2023	08:05	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
8/14/2023	08:00	PRNUS	Chemomab Therapeutics Announces Second Quarter 2023..
8/08/2023	06:00	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
7/05/2023	17:48	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
7/03/2023	15:49	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
6/28/2023	07:00	PRNUS	Chemomab Therapeutics Announces Publication in JCI Insight..
6/26/2023	07:00	PRNUS	Chemomab Therapeutics Presents Data Reinforcing the Clinical..
6/21/2023	07:00	PRNUS	Chemomab Therapeutics Reports Positive Data from Secondary..
6/05/2023	07:00	PRNUS	Chemomab Therapeutics Announces Executive Leadership Changes..
6/02/2023	09:00	PRNUS	Patient Data Presented at 2023 EULAR Congress Highlights How..
5/24/2023	07:00	PRNUS	Chemomab Therapeutics to Participate in Upcoming Scientific..
5/11/2023	06:00	PRNUS	Chemomab Therapeutics Announces First Quarter 2023 Financial..